Zolmitriptan versus sumatriptan for the acute oral treatment of migraine: a randomized, double-blind, international study

European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies
K Gruffyd-JonesD Millson

Abstract

This randomized, double-blind, parallel-group study compared the efficacy and tolerability of zolmitriptan (2.5 or 5 mg) and sumatriptan (50 mg) in the acute oral treatment of up to six moderate-to-severe migraine attacks. The intention to treat (ITT) population comprised of 1522 patients: 500 treated with zolmitriptan 2.5 mg (2671 attacks), 514 with zolmitriptan 5 mg (2744 attacks) and 508 with sumatriptan 50 mg (2693 attacks). Overall, the 2-h headache response rates in these groups were 62.9, 65.7 and 66.6%, respectively. There were no statistically significant differences between sumatriptan 50 mg and zolmitriptan 2.5 mg (P = 0.12) or 5 mg (P = 0.80). Approximately 40% of patients in each group reported a 2-h headache response in > or = 80% of attacks. There were no statistically significant differences between the groups in the rates of headache response at 1 h (zolmitriptan 2.5 mg 36.9%, zolmitriptan 5 mg 39.5% and sumatriptan 50 mg 38.0%) or 4 h (70.3, 72.9 and 72.2%, respectively) or in the rates of meaningful migraine relief at 1, 2 or 4 h or sustained (24-h) pain relief. All treatments were well tolerated. In conclusion, zolmitriptan (2.5 or 5 mg) proved similarly efficacious compared with sumatriptan (50 mg), both in...Continue Reading

References

Jan 1, 1992·JAMA : the Journal of the American Medical Association·W F StewartM L Reed
Mar 1, 1988·Cephalalgia : an International Journal of Headache·F SorgeP Carrieri
Feb 1, 1995·Cephalalgia : an International Journal of Headache·C G Dahlöf, E Dimenäs
Jan 1, 1994·European Neurology·W F Stewart, R B Lipton
May 1, 1997·Cephalalgia : an International Journal of Headache·G R Martin
Dec 17, 1997·Cephalalgia : an International Journal of Headache·J Schoenen, J Sawyer
Jun 9, 1998·Drugs·C M Perry, A Markham
Dec 2, 1998·British Journal of Clinical Pharmacology·E J SeaberJ H Jonkman
Jan 20, 2000·Current Medical Research and Opinion·S J TepperD S Millson

❮ Previous
Next ❯

Citations

Apr 30, 2004·Current Pain and Headache Reports·Paul Rolan
Feb 27, 2004·Cephalalgia : an International Journal of Headache·T J SteinerC R Sikes
Jun 17, 2005·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·C VollonoG Di Trapani
May 1, 2009·Expert Review of Neurotherapeutics·Marcelo E BigalRichard Hargreaves
Aug 9, 2003·Expert Opinion on Drug Safety·Stewart J Tepper, David Millson
Jan 6, 2004·Annals of Neurology·Rami BursteinMoshe Jakubowski
Aug 16, 2016·Cephalalgia : an International Journal of Headache·Kristian ThorlundPeter J Goadsby
Feb 18, 2012·The Cochrane Database of Systematic Reviews·Christopher J DerryR Andrew Moore
May 23, 2014·The Cochrane Database of Systematic Reviews·Sarah BirdR Andrew Moore
Nov 5, 2005·CNS Drugs·Lisa K Mannix, Julia A Files
Feb 18, 2012·The Cochrane Database of Systematic Reviews·Douglas C McCrory, Rebecca N Gray
Jan 30, 2020·Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·G R TabeevaA E Shagbazyan
Oct 25, 2003·American Journal of Pharmacogenomics : Genomics-related Research in Drug Development and Clinical Practice·Kelly L RogersLyn R Griffiths
Dec 14, 2016·The Journal of Headache and Pain·Haiyang XuMingxian Li
Dec 24, 2010·Clinical Pharmacology and Therapeutics·B S LevitanF Mussen

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.